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Abstract
Radiotherapy has a not well-established role in the 
pre-operative and in the post-operative setting in 
gastric cancer (GC) patients. Randomized trials report 
controversial outcomes and impact on survival. In 
TOPIC HIGHLIGHT
Submit a Manuscript: http://www.wjgnet.com/esps/
Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
DOI: 10.3748/wjg.v22.i3.1131
World J Gastroenterol  2016 January 21; 22(3): 1131-1138
 ISSN 1007-9327 (print)  ISSN 2219-2840 (online)
© 2016 Baishideng Publishing Group Inc. All rights reserved.
1131 January 21, 2016|Volume 22|Issue 3|WJG|www.wjgnet.com
2016 Gastric Cancer: Global view
the D2 loco-regional node resection era, after a well-
performed radical surgery, local treatment using 
radiotherapy combined to chemotherapy should be 
considered for locally advanced GC. Prognostic factors 
could help the better selection of subgroups that 
present high risk of loco-regional recurrence. Then, the 
addition of radiotherapy could improve the disease-
free survival and also quality of life. There are no 
large prospective studies that have assessed specific 
factors predicting for recurrence or survival, but only 
retrospective series, some of them including high 
number of patients with homogeneous characteristics. 
In locally advanced GC adding radiotherapy to the post-
operative chemotherapy seems to improve outcomes 
and quality of life. Prognostic factors such as T-stage, 
N-status, nodal ratio, and other histological factors 
should be considered to submit patients to post-
operative combined treatment. Larger prospective 
series are necessary to investigate the role of combined 
chemoradiation after radical D2-resection, especially in 
locally advanced GC. Further prospective investigations 
are needed to suggest prognostic factors that have 
significant impact on survival and recurrence, improving 
the management and outcomes, particularly in locally 
advanced GC patients.
Key words: Gastric cancer; Adjuvant radiotherapy; 
Prognostic factors; Locally advanced disease; Selected 
patients
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Core tip: This is a review of the recent literature that 
analyze the impact of prognostic factors in patients 
affected by gastric cancer (GC). The results from the 
principal clinical trials regarding treatment for GC 
patients are controversial. Adjuvant therapy for locally 
advanced disease remains undefined in different 
countries. Prognostic factors can help clinicians to select 
reduced loco-regional failure and increased survival 
rates compared to surgery alone[6], or to adjuvant 
chemotherapy alone, or to RT alone[14].
Although meta-analyses had shown a small 
survival benefit after post-operative chemotherapy[15-17] 
several studies did not demonstrate such survival 
improvement. In the current clinical practice adjuvant 
chemotherapy is routinely used for locally advanced 
GC patients after radical resection. The role of radiation 
therapy remains controversial. To date, there is no 
evidence of clear benefit of the use of radiotherapy 
in the pre-operative or post-operative setting. The 
association to adjuvant CRT can be useful in the locally 
advanced GC to prevent loco-regional relapse, but the 
real benefit on survival remains to be demonstrated 
compared to the adjuvant chemotherapy alone. 
The aim of these review is to analyze the potential 
prognostic factors that may help to select high-
risk categories of patients who may benefit from an 
adjuvant radiochemotherapy, in the era of radical 
surgery associated with D2 node dissection and 
modern techniques of radiation therapy. 
Role of adjuvant chemoRadiation 
in the Randomized tRials
In the United States, post-operative CRT has become 
the standard of care after radical surgery for locally 
advanced stage since the randomized trial by Macdonald 
et al[6] that demonstrated a significant survival benefit 
compared to surgery alone (P < 0.001), even after 
long-term follow up[18]. High rates of severe toxicities 
were observed, maybe due to the conventional two-
dimensional (2D) RT technique, which increased the 
irradiated volume and the dose to the normal tissue. 
In Europe, the most frequent approach for resec-
table GC is pre-operative and/or post-operative chemo-
therapy. In 2006, the MAGIC study demonstrated a 
5-year OS improvement (36% vs 23%, P = 0.009) 
in patients receiving pre-operative chemotherapy and 
subsequent post-operative chemotherapy compared 
to those receiving surgery alone[8]. The main limit of 
this trial was the low adherence to the postoperative 
chemotherapy, administered to 55% of the patients; 
only 42% of the patients received the entire treatment 
because of cancer progression, surgical complications, 
and toxicity.
The National Cancer Center in South Korea 
conducted a phase Ⅲ trial that enrolled only locally 
advanced GC patients (stage Ⅲ/Ⅳ M0) who underwent 
D2-dissection to compare post-operative chemotherapy 
alone versus CRT (INT-0116 regimen)[19]. The study 
was closed due to poor accrual, but the addition of 
RT significantly prolonged the 5-year loco-regional 
recurrence-free survival (93.2% vs 66.8%, P = 0.014) 
and DFS rates (73.5% vs 54.6%, P = 0.056) compared 
to chemotherapy alone.
High rates of severe toxicities have been described 
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those patients who can benefit more from combined 
post-operative therapy with radiochemotherapy and 
should be considered in the multidisciplinary meetings. 
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intRoduction
Gastric cancer (GC) is the sixth most common type of 
cancer in Europe and has a poor prognosis. The 10-year 
survival for all stages is around 20%[1]. Asian patients 
have significantly longer median survival (35 mo vs 23 
mo, P < 0.0001) than the Caucasian population[2]. The 
5-year survival for GC is 54%-58% in Japan and South 
Korea and about 40% in other countries[3,4]. Surgery 
is the primary treatment for patients with resectable 
GC, but the prognosis of advanced GC remains poor. 
Therefore, a multidisciplinary approaches required due 
to the high risk of loco-regional and distant recurrence 
of GC. Several studies were conducted to find the 
optimal chemotherapy regimen and radiotherapy 
(RT) patterns in order to reduce toxicity rates and to 
increase the efficacy.
Several treatment strategies that include adjuvant 
chemotherapy, adjuvant chemoradiotherapy (CRT), and 
pre-operative chemotherapy have been evaluated[5-8]. 
Also, more intensified regimens have been evaluated 
in advanced stage GC, but high toxicity rates have 
been observed. In resectable GC, the benefit of 
adjuvant chemotherapy has been clearly demonstrated, 
principally in the locally advanced disease, because 
of the propensity of this disease to develop distant 
metastases. Even though, from recent randomized 
trials has emerged that in D2-resected GC patients 
the addition of radiotherapy to chemotherapy does not 
appear to provide any additional advantage[5].
Radical surgery associated to D2 lymph node 
dissection is widely used for advanced GC[9,10], but 
there are controversial data in the literature. Studies 
demonstrated rates of 3-year overall survival (OS), 
disease-free survival (DFS) and local control of 60.6%, 
54.1% and 84.3%, respectively, in patients that received 
a D2 node resection and adjuvant chemoradiation[11]. 
Others reported rates of distant relapse from 30% to 
50%[12]. A multidisciplinary management, including 
neoadjuvant combined treatment and targeted therapy 
has emerged for advanced GC resulting in increased 
curability and improved survival[13].
Adjuvant radiotherapy associated to concurrent 
chemotherapy was demonstrated to have favourable 
effects on survival and disease control. Post-operative 
combined treatment in high-risk patients with GC 
in patients treated with combined adjuvant therapy 
due to 2D RT technique that increased the irradiated 
volume. Modern RT techniques such as 3D conformal 
RT and intensity modulated radiotherapy (IMRT) allow 
high doses to be delivered to the target and lower 
doses to the surrounding sparing normal tissues 
leading to lower toxicity rates[20].
The ARTIST trial investigated the role of post-
operative CRT (capecitabine + cisplatin followed by 
capecitabineand concurrent RT 45Gy) vs chemotherapy 
alone (capecitabine + cisplatin) in 458 patients with 
curatively resected GC who underwent D2 lymph 
node dissection[7]. Overall, the addition of RT to the 
chemotherapy did not significantly prolong DFS. 
However, in the subgroup of patients with positive 
pathologic lymph nodes at the time of surgery (n = 
396), randomly assigned to the adjuvant chemoradiation 
arm experienced superior DFS when compared with 
those who received chemotherapy alone (P = 0.0365). 
The statistical significance was retained at multivariate 
analysis (P = 0.047). Only the 41% of the patients had 
a locally advanced stage in the ARTIST trial, including 
also a high percentage of patients with early stage who 
may present low risk of loco-regional recurrence after a 
well-conducted D2-resection. The principal randomized 
studies, their outcomes and limits are summarized in 
Table 1. 
The ongoing ARTIST Ⅱ trial aims to evaluate this 
issue; the benefit of adjuvant combined therapy only 
in pN+ patients. The ongoing CRITICS trial aims to 
evaluate the clinical outcome in patients treated with 
pre-operative chemotherapy (epirubicin, cisplatin and 
capecitabine) followed by surgery with adequate node 
dissection and concurrent chemoradiation (45 Gy, 
cisplatin and capecitabine)[21]. 
The role of adjuvant RT remains unclear after an 
adequate lymphadenectomy, but is seems that a 
selected category of patients may benefit from local 
treatments having also impact on survival.
Post-oPeRative chemoRadiation 
afteR d2 lymPh node Resection
However, it is difficult to estimate the N stage, to 
predict survival rate in each stage and to decide 
treatment pre-operatively based on the clinical TNM 
stage[22]. In the INT-0116 a longer survival was 
demonstrated for patients in the chemoradiation arm, 
but the study was criticized because only 10% of 
included patients underwent a D2 lymphadenectomy 
(Figure 1). Therefore, the benefit of extended lymph- 
adenectomy (D2/D3) remains a controversial issue[6]. 
In Eastern countries, the D2 node dissection is 
widely performed as standard surgical procedure. A 
Korean study demonstrated an advantage of adjuvant 
CRT for patients with GC who underwent D2 node 
resection[23]. On the other hand, a Dutch randomized 
trial[24] did not support a survival improvement even 
after a long-term follow-up of 15 years, but showed 
lower loco-regional recurrence and GC-related death 
in the D2-group compared to the D1 group (Figure 2). 
Moreover, a higher rates of complications and post-
operative deaths after D2 dissection[25-27].
The current opinion in the identification of high-
risk subgroups for loco-regional recurrence among D2-
dissected patients is of higher priority than assessing 
adjuvant CRT in all D2-dissected GC patients, prin-
cipally after the recent ARTIST trial results[7].
The subgroup analysis in the ACTS-GC trial demon-
strated a survival advantage after post-operative 
S-1 chemotherapy compared to observation in very 
advanced stage GC with pN3 nodal involvement over 
N0-N2 patients[28]. These findings may indicate that 
the employment of RT could improve outcomes in 
patients at high risk for loco-regional recurrence with 
high number of positive lymph nodes. 
Only a few small prospective or retrospective 
studies have investigated the role of adjuvant CRT 
in D2-dissected GC patients[23,29-31], reporting lower 
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Table 1  Characteristics and outcomes of principal phase Ⅲ randomized trials that compared radiotherapy associated to 
chemotherapy or chemotherapy in patients affected by gastric cancer
Trial Year Surgery (node 
resection)
Locally 
advanced
Randomization 
scheme
RT dose RT technique Median FU OS DFS, PFS Limits
SWOG/
INT-0116[6]
2001 D1 90% 85% S-alone vs 
S + CRT
45 Gy 2D 60 mo 3-yr: 
50% vs 41% 
(P = 0.005)
3-yr: 
48% vs 31% 
(P < 0.001)
Low rates of D2 
node dissectionD2 10%
MAGIC[8] 2006 D1 35% 71% S-alone 
vs CT + S + CT
- - 49 mo 5-yr: 
23% vs 36% 
(P = 0.009)
3-yr: 
26% vs 38% 
(P < 0.001)
Low adherence 
to post-operative 
CT
D2 77%
NCC, 
South Korea[19]
2012 D2 100% 98% S + CT vs 
S + CRT
45 Gy 2D/3D 87 mo 5-yr: 
65% vs 55% 
(P > 0.05)
5-yr: 
61% vs 50% 
(P > 0.05)
Poor accrual
ARTIST[7] 2012 D2 100% 86% S + CT + CRT + 
CT vs S + CT
45 Gy 2D/3D 53 mo NR 3-yr: 
78% vs 74% 
(P = 0.086)
Planned events 
not reached
RT: Radiotherapy; FU: Follow up; OS: Overall survival; DFS: Disease-free survival; PFS: Progression-free survival; S: Surgery; CT: Chemotherapy; CRT: 
Chemoradiotherapy; 2D: 2-dimensional; 3D: 3-dimensional; NR: Not reported.
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INT 0116 trial
D1 D2
Lymph node dissection
10%
90%
Surgery alone
R
RT   45 Gy
5FU + LV
Surgery-only group
36 mo
P  = 0.005
Median survival
CRT group (45 Gy)
27 mo
were similar in the two treatment groups.
The D2 dissection has been recently recommended 
as the standard surgical method worldwide, data 
on the influence of clinical results is now available 
from both Eastern and Western studies[27]. Larger 
prospective series are necessary to investigate the role 
of combined chemoradiation after radical D2 resection, 
especially in locally advanced GC. 
t-stage, n-status and nodal Ratio
The TNM classification has an appropriate prognostic 
value for predicting the OS of GC patients after 
curative surgery[33]. Therefore, for stage IB GC patients 
(T1N1M0 and T2N0M0) the relapse rates are low 
and the OS are around 87.3%-95.5% at 3-years and 
81.8%-95.5% at 5-years, respectively, presenting 
recurrence rates obtained with adjuvant CRT after D1-
dissection, but not after D2 dissection. However, the 
updated analysis of the INT-0116 study after a median 
follow-up of 10-years[18] demonstrated a persistent 
benefit of post-operative CRT regarding the loco-
regional control of the disease, but not the distant 
recurrence. 
A randomized multicenter Chinese study[32] 
compared 45 Gy IMRT plus concurrent chemotherapy 
(C-IMRT) with chemotherapy alone in GC patients after 
D2 resection. Survival was not significantly different 
between the two groups. The C-IMRT was associated 
with increased median duration of RFS (36 mo vs 50 
mo, P = 0.029) (Figure 3). On the multivariate analysis 
lymph nodes metastases and TNM stage were both 
independent prognostic factors, but not correlated to 
treatment modality. Rates of all grade adverse events 
Figure 1  Randomization, treatment schemes and outcomes of the INT-0116 trial by Macdonald et al. LV: Leucovorin; 5-FU: 5-fluorouracil; RT: Radiotherapy; 
CRT: Chemoradiotherapy.
Dutch trial D1 vs  D2: 15-yr follow-up
Lymph node dissection
47%
D1 D2
53%
D1 - group
5 yr-survival
D2 - group
D2 - group
D1 - group
Risk of relapse 
P  = 0.22
D1 - group
D2 - group
Post-operative complications
P  < 0.001
45%
47%
43%
37%
43%
25%
Figure 2  Long-term outcomes after 15 years follow up of the Dutch randomized trial by Bonenkamp et al D1 vs D2 node dissection. 
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lower rates for upper third located tumors, when no 
post-operative therapy is administered after radical 
resection[34]. This means that locally advanced stage 
could benefit more from an intensified additional 
treatment with chemotherapy associated or not to 
radiotherapy.
Prognostic factors could help the better selection 
of subgroups that present high risk of loco-regional 
recurrence. Then, the addition of radiotherapy could 
improve the DFS and also quality of life. There are no 
large prospective studies that have assessed specific 
factors predicting for recurrence or survival, but only 
retrospective series, some of them including high 
number of patients with homogeneous characteristics.
Gross inspection and the macroscopic diagnosis 
of tumor invasion through the serosa seem to have 
a strong impact on tumor recurrence in GC patients. 
A total of 370 patients with locally advanced pT2-T4a 
GC who underwent curative surgery were evaluated 
for potential correlation between pT-stage and 
recurrence[35]. Significant differences were observed in 
the 5-year DFS according to the pathological T-stage 
between pT2 (83.2%), pT3 (64.5%), and T4a (28.0%) 
patients. On the multivariate analysis macroscopic 
diagnosis (P = 0.019) and lymph node metastasis (P 
< 0.001) were independent risk factors for recurrence. 
Consequently, the gross appearance of serosal invasion 
should be considered as a factor to predict prognosis 
and to select high-risk patients.
A retrospective study from a large series of 244 
patients with long term follow up time (median 99 
mo) treated with postoperative CRT (46 Gy) vs RT 
alone, analyzed long-term survival probability and the 
impact of variables on survival[36]. The 1-, 3-, 5- and 
10-year actuarial OS were 79%, 37%, 24% and 16%, 
respectively. Actuarial progression free survival was 
69%, 34%, 23% and 16% in the same consecutive 
order. On the multivariate analysis, stage Ⅰ-Ⅱ 
disease, subtotal gastrectomy and adjuvant CRT were 
significantly associated with improved OS and PFS. 
Surgical margin status and/or lymph node dissection 
type (D0 vs D1 vs D2-3) were not prognostic factors 
for survival.
A multicenter retrospective analysis of 232 patients 
with pT3 GC who underwent curative gastrectomy 
and D2 node dissection demonstrated that the median 
survival of patients with small tumor size (≤ 8 cm) 
was significantly better than for patients with large 
tumor size (> 8 cm) (107 mo vs 18.2 mo, P < 0.001). 
In the univariate analysis, tumor size (P < 0.001), pN 
stage (P = 0.000), metastatic lymph node ratio (LNR) 
(P = 0.005), lymphatic vessel invasion (P = 0.000), 
blood vessel invasion (P = 0.000), and perineural 
invasion (P = 0.006), were found to be significant 
prognostic factors for OS[37].
Kim et al[38] showed after a retrospective analysis 
of 679 resected GC patients that pre-operative CA125 
level was an independent risk factor for distant/loco-
regional recurrence (P = 0.02).
The lymph node status and a cut-off of ratio 
between the involved and the removed lymph nodes 
have consented to select patients with better prognosis. 
The involvement of 1-2 lymph nodes (N1) was 
associated with a better prognosis compared to N2 (3-6 
positive nodes) involvement with a significant difference 
in (P = 0.04) 5-year OS rates (67.5% for N1 vs 43% 
for N2)[39].
Usually, the LNR is higher in patients with stage Ⅲ 
GC than in those with stage Ⅰ or Ⅱ disease. Advanced 
stage patients with GC are more at risk to develop 
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D1 D2
Chinese trial
Lymph node dissection
100%
R
IMRT   45 Gy
5FU + LV
C-alone group
36 mo
P  = 0.029
Median recurrence-free survival
C-IMRT group
50 mo
5FU + LV
Figure 3  Randomization, treatment schemes and outcomes of the Chinese trial by Zhu et al. LV: Leucovorin; 5-FU: 5-fluorouracil; IMRT: Intensity modulated 
radiotherapy; C: Chemotherapy.
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loco-regional/distant relapse. The prognostic value 
of metastatic LNR was investigated in patients who 
received radical resection and D2 lymphadenectomy in 
365 patients with stage Ⅲ gastric GC[40]. The LNR is an 
independent prognostic factor for survival in stage Ⅲ 
GC and is superior to the pN category in TNM staging. 
It may be considered as a prognostic variable in future 
staging system.
Prognostic factors were evaluated in 120 resected 
GC patients treated in a single Institution using the 
Intergroup 0116 study regimen[41]. On multivariate 
analysis, surgical positive margin and advanced sage 
were significant prognostic factors for loco-regional 
recurrence (P = 0.03, P = 0.04).
A SEER database that investigated the impact 
postoperative radiotherapy on survivals in the INT0116 
results, reported among lymph node-positive patients 
a significant survival benefit from RT compared with 
no-RT (P < 0.0001)[42]. The median survival and the 
5-year OS among lymph node-positive patients were 
29 mo and 34%, respectively, for post-operative RT 
group, and 19 mo and 20%, respectively, for no-RT. 
The multivariate analysis demonstrated that removing 
≥ 15 lymph nodes was an independent predictor for 
improved survival, whereas tumor classification, lymph 
node status, tumor size, and tumor location were 
independent predictors of death.
A retrospective study including patients with GC 
who underwent D2 lymphadenectomy followed by 
adjuvant CRT or was not analyzed to find individuals 
category that could benefit from combined post-
operative treatment. Patients who had lymph node 
metastasis presented a significant improvement in 
OS (P = 0.023) with the addition of adjuvant CRT[43]. 
Patients with N1 and N2 tumors and higher N-ratio had 
similarly superior survival numbers with the addition of 
CRT, even the results were not statistically significant.
Another retrospective study[44], including only 
patients affected by locally advanced GC (T3-4 and/
orN+) who underwent gastrectomy + D2 lymph node 
dissection followed by adjuvant CRT, or CRT + intra-
operative radiotherapy (IORT) 12-15Gy, revealed that 
adjuvant IORT was an independent prognostic factor 
for both loco-regional control and OS (P = 0.02 and 
P = 0.04, respectively). Other significant prognostic 
factors for loco-regional control included the positive 
surgical margin (P = 0.005) and positive pN status (P 
= 0.03). In contrast, pT and pN stage were significant 
prognostic factors for OS. Intensified local therapy 
could also improve survival in locally advanced stage 
GC patients, in particular in those with high number of 
positive lymph nodes at the histological examination 
allowing acceptable toxicity rates. Other recent 
retrospective studies reported that LNR and N-stage 
were the most important prognostic factors for OS, 
DFS and loco-regional control[12,41,45].
Considering the above reported outcomes, the 
addition of radiation therapy could improve the RFS in 
patients with large gastric tumors, advanced stage and 
high number of involved lymph nodes even after D2-
resection. 
Positive suRgical maRgin (R1), 
histological subtyPe and 
PeRineuRal invasion
A microscopically positive (R1) resection is an adverse 
prognostic factor GC patients after radical surgery[46]. 
However, the prognostic significance of an R1 resection 
in GC patients treated with post-operative CRT has 
been hardly studied. The surgical margin status was 
rarely evaluated as a prognostic factor to recurrence. 
A retrospective analysis included 110 patients to 
evaluate the effect of an R1 resection on RFS in GC 
patients who received CRT (45 Gy/25 fractions) after 
surgery. Three-year RFS (45% vs 35%, P = 0.34) and 
OS (47% vs 48%, P = 0.58) did not significantly differ 
between patients who had undergone an R0 or R1 
resection[47]. Maybe the adjuvant CRT is useful in this 
subgroup of patients, but larger series are necessary to 
confirm this issue. In a recent update of the INT-0116 
study, the benefit of adjuvant CRT after a radical (R0) 
resection for GC was confirmed[18].
There are no studies assessing histological 
subtype for predicting response to therapy, relapse or 
survival. There is reported that intestinal subtype is 
more common and less aggressive compared to the 
diffuse subtype. Lauren classification has emerged 
as a significant independent predictors of survival 
in retrospective analysis[48], but less is known about 
patterns of recurrences in this subgroup of patients 
affected by locally advanced GC. No direct correlation 
with local recurrences still described in the literature.
Perineural invasion (PI) has been investigated as 
a possible prognostic factor in 30590 GC patients 
who had undergone curative gastrectomy from 24 
studies. The median rate of positive PI was 41% and it 
resulted an independent prognostic factor for OS and 
recurrence (P = 0.000, respectively), but this effect 
was independent of lymph node status, tumor size and 
the depth of invasion on multivariate analysis[49].
Patients affected by advanced GC that present 
some particular characteristics at the definitive 
histological examination such as positive surgical 
margin (R1), PI, or diffuse histological subtype may 
be considered as high-risk categories. These finding 
are supported only by some retrospective analyses 
and seem to significantly correlate with survival[36,43]. 
This category of patients may benefit from more 
intensified treatment adding local irradiation to prevent 
recurrence.
conclusion
Nowadays, radiotherapy has a not well-established 
role in the pre-operative and in the post-operative 
setting in GC patients. Randomized trials report 
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controversial outcomes and impact on survival. In 
the D2 resection era, after a well-performed radical 
surgery, local treatment using radiotherapy combined 
to chemotherapy should be considered for locally 
advanced GC. Even there are no strict indications 
to combined adjuvant therapy, a multidisciplinary 
discussion should guide definitive decision. Prognostic 
factors may help clinicians to select high-risk categories 
of patients who may benefit from a more intensified 
regimen including radiotherapy. Unfortunately, only 
retrospective series indicate selection criteria providing 
low level of evidence, but large and homogeneous 
population of patients have been evaluated. Further 
prospective investigations are needed to suggest 
prognostic factors that have significant impact on 
survival and recurrence, improving the management 
and outcomes, particularly in locally advanced GC 
patients.
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